HIV-1–specific CD4+ T lymphocyte turnover and activation increase upon viral rebound
HIV-specific CD4+ T helper lymphocytes are preferred targets for infection. Although complete interruption of combination antiretroviral therapy (ART) can form part of therapeutic manipulations, there is grave concern that the resumption of viral replication might destroy, perhaps irreversibly, thes...
Saved in:
Published in | The Journal of clinical investigation Vol. 115; no. 2; pp. 443 - 450 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Society for Clinical Investigation
01.02.2005
|
Subjects | |
Online Access | Get full text |
ISSN | 0021-9738 |
DOI | 10.1172/JCI200523084 |
Cover
Abstract | HIV-specific CD4+ T helper lymphocytes are preferred targets for infection. Although complete interruption of combination antiretroviral therapy (ART) can form part of therapeutic manipulations, there is grave concern that the resumption of viral replication might destroy, perhaps irreversibly, these T helper populations. High viremia blocks the proliferation capacity of HIV-specific helper cells. However, cytokine production assays imply that some antigen-specific effector function is retained. Despite this careful work, it remains unclear whether the return of HIV-1 replication physically destroys HIV-1-specific T helper cells in the peripheral blood. Difficulties in producing stable peptide-MHC class II complexes and the very low frequencies of antigen-specific CD4+ T cells have delayed the application of this powerful technique. Here we employ HLA class II tetramers and validate a sensitive, quantitative cell-enrichment technique to detect HIV-1 T helper cells. We studied patients with early-stage HIV infection who were given a short, fixed course of ART as part of a clinical study. We did not find significant deletion of these cells from the peripheral circulation when ART was stopped and unfettered HIV replication returned. The turnover of these virus-specific cells increased and they adopted an effector phenotype when viremia returned. |
---|---|
AbstractList | HIV-specific CD4
+
T helper lymphocytes are preferred targets for infection. Although complete interruption of combination antiretroviral therapy (ART) can form part of therapeutic manipulations, there is grave concern that the resumption of viral replication might destroy, perhaps irreversibly, these T helper populations. High viremia blocks the proliferation capacity of HIV-specific helper cells. However, cytokine production assays imply that some antigen-specific effector function is retained. Despite this careful work, it remains unclear whether the return of HIV-1 replication physically destroys HIV-1–specific T helper cells in the peripheral blood. Difficulties in producing stable peptide-MHC class II complexes and the very low frequencies of antigen-specific CD4
+
T cells have delayed the application of this powerful technique. Here we employ HLA class II tetramers and validate a sensitive, quantitative cell-enrichment technique to detect HIV-1 T helper cells. We studied patients with early-stage HIV infection who were given a short, fixed course of ART as part of a clinical study. We did not find significant deletion of these cells from the peripheral circulation when ART was stopped and unfettered HIV replication returned. The turnover of these virus-specific cells increased and they adopted an effector phenotype when viremia returned. HIV-specific CD4+ T helper lymphocytes are preferred targets for infection. Although complete interruption of combination antiretroviral therapy (ART) can form part of therapeutic manipulations, there is grave concern that the resumption of viral replication might destroy, perhaps irreversibly, these T helper populations. High viremia blocks the proliferation capacity of HIV-specific helper cells. However, cytokine production assays imply that some antigen-specific effector function is retained. Despite this careful work, it remains unclear whether the return of HIV-1 replication physically destroys HIV-1-specific T helper cells in the peripheral blood. Difficulties in producing stable peptide-MHC class II complexes and the very low frequencies of antigen-specific CD4+ T cells have delayed the application of this powerful technique. Here we employ HLA class II tetramers and validate a sensitive, quantitative cell-enrichment technique to detect HIV-1 T helper cells. We studied patients with early-stage HIV infection who were given a short, fixed course of ART as part of a clinical study. We did not find significant deletion of these cells from the peripheral circulation when ART was stopped and unfettered HIV replication returned. The turnover of these virus-specific cells increased and they adopted an effector phenotype when viremia returned. |
Author | Klenerman, Paul Zhang, Hua-Tang Oxenius, Annette Day, Cheryl L. Tamm, Norbert Brown, Helen L. Phillips, Rodney E. Scriba, Thomas J. Fidler, Sarah Weber, Jonathan N. Fox, Julie Lucas, Michaela |
AuthorAffiliation | 1 Peter Medawar Building for Pathogen Research and Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom. 2 Institute for Microbiology, Eidgenössische Technische Hochschule Zurich, Zurich, Switzerland. 3 Department of Medicine, Imperial College, St. Mary’s Hospital, London, United Kingdom |
AuthorAffiliation_xml | – name: 1 Peter Medawar Building for Pathogen Research and Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom. 2 Institute for Microbiology, Eidgenössische Technische Hochschule Zurich, Zurich, Switzerland. 3 Department of Medicine, Imperial College, St. Mary’s Hospital, London, United Kingdom |
Author_xml | – sequence: 1 givenname: Thomas J. surname: Scriba fullname: Scriba, Thomas J. – sequence: 2 givenname: Hua-Tang surname: Zhang fullname: Zhang, Hua-Tang – sequence: 3 givenname: Helen L. surname: Brown fullname: Brown, Helen L. – sequence: 4 givenname: Annette surname: Oxenius fullname: Oxenius, Annette – sequence: 5 givenname: Norbert surname: Tamm fullname: Tamm, Norbert – sequence: 6 givenname: Sarah surname: Fidler fullname: Fidler, Sarah – sequence: 7 givenname: Julie surname: Fox fullname: Fox, Julie – sequence: 8 givenname: Jonathan N. surname: Weber fullname: Weber, Jonathan N. – sequence: 9 givenname: Paul surname: Klenerman fullname: Klenerman, Paul – sequence: 10 givenname: Cheryl L. surname: Day fullname: Day, Cheryl L. – sequence: 11 givenname: Michaela surname: Lucas fullname: Lucas, Michaela – sequence: 12 givenname: Rodney E. surname: Phillips fullname: Phillips, Rodney E. |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/15668739$$D View this record in MEDLINE/PubMed |
BookMark | eNptkMlOwzAQhn0oogvcOCPfIeB4SZwDBxSWFlXiUnqNHMemRqkdOYvUG-_AG_IkBMpSEKfRaL5_ZvSNwcA6qwA4CtFZGMb4_C6dYYQYJojTARghhMMgiQkfgnFdPyEUUsroPhiGLIp4TJIRWE5nyyB8fX6pKyWNNhKmV_QELmC5WVcrJzeNgk3rreuUh8IWUMjGdKIxzkJjpVeiVrCt-q4zXpTQq9y1tjgAe1qUtTr8rBPwcHO9SKfB_P52ll7OA0kYagJMRBEprZAmgrAExRprQqIkYYTFueBxLguqVaKlyDljOOdJjBRHUpMi4gqRCbjY7q3afK0KqWzTf5FV3qyF32ROmOz3xJpV9ui6jFEaIdbnj3fz38EvQT1wugWkd3Xtlf5BUPbuPNt13uP4Dy5N82Grv27K_0NvB3-H9g |
CitedBy_id | crossref_primary_10_4049_jimmunol_175_10_6948 crossref_primary_10_1002_eji_200635886 crossref_primary_10_1128_JVI_00056_12 crossref_primary_10_1007_s11904_006_0002_5 crossref_primary_10_1128_JVI_00485_08 crossref_primary_10_1084_jem_20121437 crossref_primary_10_1016_j_clim_2015_02_009 crossref_primary_10_1371_journal_ppat_0030144 crossref_primary_10_1097_01_aids_0000176224_56108_fb crossref_primary_10_1097_01_COH_0000194103_28063_35 crossref_primary_10_1097_01_COH_0000194107_20439_91 crossref_primary_10_1002_eji_200737648 crossref_primary_10_1016_j_virol_2006_10_040 crossref_primary_10_1086_522966 crossref_primary_10_1371_journal_ppat_1005832 crossref_primary_10_4161_hv_18432 crossref_primary_10_1111_j_1365_2249_2006_03193_x crossref_primary_10_1164_rccm_200907_1011OC crossref_primary_10_1371_journal_pone_0000649 crossref_primary_10_1586_erv_10_66 crossref_primary_10_1128_JVI_00249_06 crossref_primary_10_4049_jimmunol_1000156 crossref_primary_10_1007_s11010_009_0293_0 crossref_primary_10_1038_sj_icb_7100015 crossref_primary_10_1042_CS20050157 crossref_primary_10_1371_journal_pone_0000300 crossref_primary_10_1002_hep_20669 crossref_primary_10_1038_ni1241 crossref_primary_10_1128_JVI_00070_06 crossref_primary_10_1172_JCI46023 crossref_primary_10_1097_QAI_0b013e3181aeccdc crossref_primary_10_1371_journal_pone_0188250 crossref_primary_10_1002_cyto_a_20603 crossref_primary_10_1111_j_1365_2567_2007_02801_x crossref_primary_10_1016_j_it_2005_07_005 crossref_primary_10_1089_vim_2019_0186 crossref_primary_10_1097_COH_0b013e328011aab1 crossref_primary_10_1002_eji_200940102 crossref_primary_10_4049_jimmunol_175_10_6334 crossref_primary_10_1097_QAD_0b013e328339fe0b crossref_primary_10_1111_j_1365_2249_2008_03653_x crossref_primary_10_4049_jimmunol_0803548 |
Cites_doi | 10.1182/blood-2003-04-1203 10.1038/8400 10.1002/eji.200424898 10.1086/318545 10.1073/pnas.97.10.5393 10.1084/jem.194.9.1277 10.1073/pnas.97.7.3382 10.1128/JVI.75.24.11983-11991.2001 10.1038/35035103 10.1002/(SICI)1521-4141(199906)29:06<2037::AID-IMMU2037>3.0.CO;2-V 10.1128/JVI.77.20.10900-10909.2003 10.1146/annurev.immunol.22.012703.104702 10.4049/jimmunol.159.4.1686 10.1073/pnas.190335897 10.1182/blood-2001-11-0080 10.1097/00002030-200210180-00010 10.1084/jem.187.8.1295 10.1086/342559 10.1089/088922299310485 10.1084/jem.191.9.1499 10.1172/JCI200318509 10.1128/JVI.76.12.5925-5936.2002 10.1073/pnas.251539598 10.1172/JCI8476 10.1111/j.1399-0039.1995.tb03127.x 10.1002/1521-4141(200112)31:12<3782::AID-IMMU3782>3.0.CO;2-# 10.1073/pnas.250472097 10.1182/blood-2003-09-3333 10.4049/jimmunol.172.5.3337 10.1084/jem.20041270 10.1086/315202 10.1086/315379 10.1073/pnas.202372199 10.1172/JCI8943 10.1073/pnas.96.26.15109 10.1038/44385 10.1038/417095a 10.1084/jem.20031598 10.4049/jimmunol.167.11.6663 10.1128/JVI.78.13.7284-7287.2004 10.1126/science.278.5342.1447 10.1038/4772 |
ContentType | Journal Article |
Copyright | Copyright © 2005, American Society for Clinical Investigation 2005 |
Copyright_xml | – notice: Copyright © 2005, American Society for Clinical Investigation 2005 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 5PM |
DOI | 10.1172/JCI200523084 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EndPage | 450 |
ExternalDocumentID | PMC544605 15668739 10_1172_JCI200523084 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- -~X .55 .GJ .XZ 08G 08P 29K 2WC 354 36B 53G 5GY 5RE 5RS 7RV 7X7 88E 8AO 8F7 8FE 8FH 8FI 8FJ 8R4 8R5 AAWTL AAYOK AAYXX ABOCM ABPMR ABUWG ACGFO ACIHN ACNCT ACPRK ADBBV AEAQA AENEX AFCHL AFFNX AFKRA AHMBA AI. ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS ASPBG AVWKF AZFZN BAWUL BBNVY BCR BCU BEC BENPR BHPHI BKEYQ BLC BPHCQ BVXVI CCPQU CITATION CS3 D-I DIK DU5 E3Z EBD EBS EJD EMB EMOBN EX3 F5P FRP FYUFA GROUPED_DOAJ GX1 HCIFZ HMCUK HYE H~9 IAO IEA IHR INH IOF IPO KQ8 L7B LK8 M1P M5~ M7P MVM N4W NAPCQ OBH OCB ODZKP OFXIZ OGEVE OHH OK1 OVD OVIDX OVT P2P P6G PHGZM PHGZT PQQKQ PROAC PSQYO Q2X RPM S0X SJFOW SV3 TEORI TR2 TVE UKHRP VH1 VVN W2D WH7 WOQ WOW X7M XSB YFH YHG YKV YOC ZXP ZY1 ~H1 3O- 3V. 88A AAKAS ADZCM CGR CUY CVF ECM EIF FEDTE HVGLF IHW INR IOV ISR ITC J5H M0L NPM OHT PKN UHU ZGI 5PM PJZUB PPXIY PQGLB |
ID | FETCH-LOGICAL-c350t-23ad6efe0f3a35907f2f336995357ba87bcd4fe9fcab8552b8970e80cf3d68e03 |
ISSN | 0021-9738 |
IngestDate | Thu Aug 21 14:07:58 EDT 2025 Wed Feb 19 01:43:11 EST 2025 Thu Apr 24 23:01:38 EDT 2025 Tue Jul 01 03:47:52 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c350t-23ad6efe0f3a35907f2f336995357ba87bcd4fe9fcab8552b8970e80cf3d68e03 |
Notes | Address correspondence to: Rodney E. Phillips, The Peter Medawar Building for Pathogen Research, South Parks Road, Oxford OX1 3SY, United Kingdom. Phone: 44-1865-281230; Fax: 44-1865-281890; E-mail: rodney.phillips@ndm.ox.ac.uk. |
OpenAccessLink | http://doi.org/10.1172/JCI200523084 |
PMID | 15668739 |
PageCount | 8 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_544605 pubmed_primary_15668739 crossref_primary_10_1172_JCI200523084 crossref_citationtrail_10_1172_JCI200523084 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2005-02-01 |
PublicationDateYYYYMMDD | 2005-02-01 |
PublicationDate_xml | – month: 02 year: 2005 text: 2005-02-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | The Journal of clinical investigation |
PublicationTitleAlternate | J Clin Invest |
PublicationYear | 2005 |
Publisher | American Society for Clinical Investigation |
Publisher_xml | – name: American Society for Clinical Investigation |
References | B20 B23 B24 B25 B26 B27 B28 Chao (B21) 1997; 159 B30 B31 B10 B32 B11 B33 B12 Day (B22) 2003; 112 B34 B13 B35 Bunce (B42) 1995; 46 B14 B36 B15 B37 B38 B17 B39 B18 B19 Douek (B29) 2001; 167 B1 B2 Palmer (B16) 2004; 172 B3 B4 B5 B6 B7 B8 B9 B40 B41 11696593 - J Exp Med. 2001 Nov 5;194(9):1277-87 15381726 - J Exp Med. 2004 Sep 20;200(6):701-12 14676302 - J Exp Med. 2003 Dec 15;198(12):1909-22 10608758 - J Infect Dis. 2000 Jan;181(1):121-31 10382767 - Eur J Immunol. 1999 Jun;29(6):2037-45 10537110 - Nature. 1999 Oct 14;401(6754):708-12 10606619 - J Clin Invest. 1999 Dec;104(12):1669-70 10762561 - J Infect Dis. 2000 Apr;181(4):1249-63 11095734 - Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13778-83 9367954 - Science. 1997 Nov 21;278(5342):1447-50 10737796 - Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3382-7 9257829 - J Immunol. 1997 Aug 15;159(4):1686-94 14978142 - J Immunol. 2004 Mar 1;172(5):3337-47 15032595 - Annu Rev Immunol. 2004;22:745-63 15162426 - Eur J Immunol. 2004 Jun;34(6):1570-7 12975468 - J Clin Invest. 2003 Sep;112(6):831-42 10229228 - Nat Med. 1999 May;5(5):518-25 11714838 - J Immunol. 2001 Dec 1;167(11):6663-8 10805798 - Proc Natl Acad Sci U S A. 2000 May 9;97(10):5393-8 11717444 - Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13878-83 11029005 - Nature. 2000 Sep 28;407(6803):523-6 12958069 - Blood. 2004 Feb 1;103(3):966-72 10611346 - Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15109-14 11005833 - Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11433-8 11745399 - Eur J Immunol. 2001 Dec;31(12):3782-8 9883844 - Nat Med. 1999 Jan;5(1):83-9 10790425 - J Exp Med. 2000 May 1;191(9):1499-512 12149221 - Blood. 2002 Aug 15;100(4):1381-7 8838344 - Tissue Antigens. 1995 Nov;46(5):355-67 10606632 - J Clin Invest. 1999 Dec;104(12):R63-7 11711588 - J Virol. 2001 Dec;75(24):11983-91 11170994 - J Infect Dis. 2001 Feb 15;183(4):657-61 12370504 - AIDS. 2002 Oct 18;16(15):2049-54 9547340 - J Exp Med. 1998 Apr 20;187(8):1295-303 12021325 - J Virol. 2002 Jun;76(12):5925-36 15194806 - J Virol. 2004 Jul;78(13):7284-7 10445809 - AIDS Res Hum Retroviruses. 1999 Jul 20;15(11):973-81 12195350 - J Infect Dis. 2002 Sep 1;186(5):634-43 14512540 - J Virol. 2003 Oct;77(20):10900-9 15117761 - Blood. 2004 Aug 15;104(4):942-7 11986671 - Nature. 2002 May 2;417(6884):95-8 12370434 - Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13747-52 |
References_xml | – ident: B18 doi: 10.1182/blood-2003-04-1203 – ident: B12 doi: 10.1038/8400 – ident: B25 doi: 10.1002/eji.200424898 – ident: B7 doi: 10.1086/318545 – ident: B30 doi: 10.1073/pnas.97.10.5393 – ident: B28 doi: 10.1084/jem.194.9.1277 – ident: B40 doi: 10.1073/pnas.97.7.3382 – ident: B10 doi: 10.1128/JVI.75.24.11983-11991.2001 – ident: B13 doi: 10.1038/35035103 – ident: B20 doi: 10.1002/(SICI)1521-4141(199906)29:06<2037::AID-IMMU2037>3.0.CO;2-V – ident: B14 doi: 10.1128/JVI.77.20.10900-10909.2003 – ident: B39 doi: 10.1146/annurev.immunol.22.012703.104702 – volume: 159 start-page: 1686 year: 1997 ident: B21 publication-title: J. Immunol. doi: 10.4049/jimmunol.159.4.1686 – ident: B26 doi: 10.1073/pnas.190335897 – ident: B19 doi: 10.1182/blood-2001-11-0080 – ident: B27 doi: 10.1097/00002030-200210180-00010 – ident: B32 doi: 10.1084/jem.187.8.1295 – ident: B8 doi: 10.1086/342559 – ident: B9 doi: 10.1089/088922299310485 – ident: B24 doi: 10.1084/jem.191.9.1499 – volume: 112 start-page: 831 year: 2003 ident: B22 publication-title: J. Clin. Invest. doi: 10.1172/JCI200318509 – ident: B11 doi: 10.1128/JVI.76.12.5925-5936.2002 – ident: B2 doi: 10.1073/pnas.251539598 – ident: B34 doi: 10.1172/JCI8476 – volume: 46 start-page: 355 year: 1995 ident: B42 publication-title: Tissue Antigens. doi: 10.1111/j.1399-0039.1995.tb03127.x – ident: B36 doi: 10.1002/1521-4141(200112)31:12<3782::AID-IMMU3782>3.0.CO;2-# – ident: B33 doi: 10.1073/pnas.250472097 – ident: B37 doi: 10.1182/blood-2003-09-3333 – volume: 172 start-page: 3337 year: 2004 ident: B16 publication-title: J. Immunol. doi: 10.4049/jimmunol.172.5.3337 – ident: B38 doi: 10.1084/jem.20041270 – ident: B41 doi: 10.1086/315202 – ident: B6 doi: 10.1086/315379 – ident: B4 doi: 10.1073/pnas.202372199 – ident: B35 doi: 10.1172/JCI8943 – ident: B5 doi: 10.1073/pnas.96.26.15109 – ident: B17 doi: 10.1038/44385 – ident: B3 doi: 10.1038/417095a – ident: B15 doi: 10.1084/jem.20031598 – volume: 167 start-page: 6663 year: 2001 ident: B29 publication-title: J. Immunol. doi: 10.4049/jimmunol.167.11.6663 – ident: B23 doi: 10.1128/JVI.78.13.7284-7287.2004 – ident: B1 doi: 10.1126/science.278.5342.1447 – ident: B31 doi: 10.1038/4772 – reference: 10445809 - AIDS Res Hum Retroviruses. 1999 Jul 20;15(11):973-81 – reference: 10737796 - Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3382-7 – reference: 15194806 - J Virol. 2004 Jul;78(13):7284-7 – reference: 12195350 - J Infect Dis. 2002 Sep 1;186(5):634-43 – reference: 10229228 - Nat Med. 1999 May;5(5):518-25 – reference: 14978142 - J Immunol. 2004 Mar 1;172(5):3337-47 – reference: 9883844 - Nat Med. 1999 Jan;5(1):83-9 – reference: 9367954 - Science. 1997 Nov 21;278(5342):1447-50 – reference: 11170994 - J Infect Dis. 2001 Feb 15;183(4):657-61 – reference: 9547340 - J Exp Med. 1998 Apr 20;187(8):1295-303 – reference: 10606619 - J Clin Invest. 1999 Dec;104(12):1669-70 – reference: 10606632 - J Clin Invest. 1999 Dec;104(12):R63-7 – reference: 8838344 - Tissue Antigens. 1995 Nov;46(5):355-67 – reference: 15381726 - J Exp Med. 2004 Sep 20;200(6):701-12 – reference: 11095734 - Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13778-83 – reference: 10382767 - Eur J Immunol. 1999 Jun;29(6):2037-45 – reference: 11745399 - Eur J Immunol. 2001 Dec;31(12):3782-8 – reference: 12370504 - AIDS. 2002 Oct 18;16(15):2049-54 – reference: 10537110 - Nature. 1999 Oct 14;401(6754):708-12 – reference: 11717444 - Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13878-83 – reference: 10805798 - Proc Natl Acad Sci U S A. 2000 May 9;97(10):5393-8 – reference: 11714838 - J Immunol. 2001 Dec 1;167(11):6663-8 – reference: 10611346 - Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15109-14 – reference: 15162426 - Eur J Immunol. 2004 Jun;34(6):1570-7 – reference: 10608758 - J Infect Dis. 2000 Jan;181(1):121-31 – reference: 15032595 - Annu Rev Immunol. 2004;22:745-63 – reference: 15117761 - Blood. 2004 Aug 15;104(4):942-7 – reference: 12958069 - Blood. 2004 Feb 1;103(3):966-72 – reference: 9257829 - J Immunol. 1997 Aug 15;159(4):1686-94 – reference: 11005833 - Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11433-8 – reference: 12149221 - Blood. 2002 Aug 15;100(4):1381-7 – reference: 10790425 - J Exp Med. 2000 May 1;191(9):1499-512 – reference: 11711588 - J Virol. 2001 Dec;75(24):11983-91 – reference: 11986671 - Nature. 2002 May 2;417(6884):95-8 – reference: 12975468 - J Clin Invest. 2003 Sep;112(6):831-42 – reference: 10762561 - J Infect Dis. 2000 Apr;181(4):1249-63 – reference: 11696593 - J Exp Med. 2001 Nov 5;194(9):1277-87 – reference: 12021325 - J Virol. 2002 Jun;76(12):5925-36 – reference: 12370434 - Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13747-52 – reference: 14512540 - J Virol. 2003 Oct;77(20):10900-9 – reference: 11029005 - Nature. 2000 Sep 28;407(6803):523-6 – reference: 14676302 - J Exp Med. 2003 Dec 15;198(12):1909-22 |
SSID | ssj0014454 |
Score | 2.0006952 |
Snippet | HIV-specific CD4+ T helper lymphocytes are preferred targets for infection. Although complete interruption of combination antiretroviral therapy (ART) can form... HIV-specific CD4 + T helper lymphocytes are preferred targets for infection. Although complete interruption of combination antiretroviral therapy (ART) can... |
SourceID | pubmedcentral pubmed crossref |
SourceType | Open Access Repository Index Database Enrichment Source |
StartPage | 443 |
SubjectTerms | Antiretroviral Therapy, Highly Active Cell Proliferation Cells, Cultured Histocompatibility Antigens Class II - immunology Histocompatibility Antigens Class II - pharmacology HIV Infections - drug therapy HIV Infections - immunology HIV Infections - pathology HIV-1 - physiology Humans Lymphocyte Activation - drug effects Lymphocyte Activation - immunology T-Lymphocytes, Helper-Inducer - immunology T-Lymphocytes, Helper-Inducer - pathology T-Lymphocytes, Helper-Inducer - virology Viremia - immunology Viremia - pathology Virus Activation - physiology |
Title | HIV-1–specific CD4+ T lymphocyte turnover and activation increase upon viral rebound |
URI | https://www.ncbi.nlm.nih.gov/pubmed/15668739 https://pubmed.ncbi.nlm.nih.gov/PMC544605 |
Volume | 115 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Pb9MwFLbKkBAXxG_KL_nATlZGFttxfIQC6ioGB7Jpt8p2Ha3SlE2QSIwTR-78h_wlPMd2krIhDS5Rm9qpmvfV7_nle99D6AXVKhcQhyfgTWjCLIO_VGryRCgAixWVkdptFPc_5PMDtjjiR5PJjxFrqW30jvl2aV3J_1gVzoFdXZXsP1i2vyicgNdgXziCheF4JRvP9w6T3UhXoK5o0hF_yOwN285ek5KcnIOtTs15Ywl4ltqxNb04q4lNzci6dmHjF0vaM3jnGL9O6F-7ZkvjuHWoIOti176ecj3IdAzP8z_BSqTVQD8ii50L-el5q5JSBbc5Tgd0fpC872d8_Grrdet7JrsSokBMiokKHrnNw-Lr2CDCi7n0i68v5gwoy0ZLKfPyTcErMy9Pe3HBF05AdjHby3yC2_eb29TV_sPf9SzEbv8jsuV49jV0PXPYjXmf8DyKMR70vP1PiCUUIns5nr0R3PQRzSbbdhS-lLfRrWA7_MqD6A6a2PouurEfmBX30GGHpV_ff0YUYUARwSUeMIQjhjBgCA8YwhFD2GEIdxjCAUP30cG7t-VsnoSeG4mhPG2SjKpVbiubVlRRLlNRZRWluZSccqFVIbRZscrKyihdcJ7pQorUFqmp6CovbEofoK36tLaPELa7XFspIQrLYVtMITJ28o4rJSHmFEXOp4jEm7U0QZDe9UU5WV5mmCna7kefeSGWv4x76G_3MAp2LIWgcoryDUP0A5zC-uYn9fq4U1rnzNEGHl_xq5-gmwPun6Kt5nNrn0HI2ujnHZp-A6jVlCU |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=HIV-1%E2%80%93specific+CD4%2B+T+lymphocyte+turnover+and+activation+increase+upon+viral+rebound&rft.jtitle=The+Journal+of+clinical+investigation&rft.au=Scriba%2C+Thomas+J.&rft.au=Zhang%2C+Hua-Tang&rft.au=Brown%2C+Helen+L.&rft.au=Oxenius%2C+Annette&rft.date=2005-02-01&rft.issn=0021-9738&rft.volume=115&rft.issue=2&rft.spage=443&rft.epage=450&rft_id=info:doi/10.1172%2FJCI200523084&rft.externalDBID=n%2Fa&rft.externalDocID=10_1172_JCI200523084 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-9738&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-9738&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-9738&client=summon |